Compare FORM & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FORM | IMVT |
|---|---|---|
| Founded | 1993 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.1B | 5.4B |
| IPO Year | 2002 | 2019 |
| Metric | FORM | IMVT |
|---|---|---|
| Price | $89.97 | $24.37 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 9 |
| Target Price | ★ $82.00 | $30.78 |
| AVG Volume (30 Days) | ★ 1.0M | 920.5K |
| Earning Date | 05-06-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.69 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $19.43 | N/A |
| Revenue Next Year | $7.31 | N/A |
| P/E Ratio | $128.10 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $22.58 | $12.72 |
| 52 Week High | $107.04 | $29.25 |
| Indicator | FORM | IMVT |
|---|---|---|
| Relative Strength Index (RSI) | 50.61 | 34.88 |
| Support Level | $82.35 | $21.74 |
| Resistance Level | $100.01 | $24.63 |
| Average True Range (ATR) | 4.92 | 1.15 |
| MACD | -1.62 | -0.30 |
| Stochastic Oscillator | 29.94 | 0.00 |
FormFactor Inc is a provider of electrical and optical test and measurement technologies along the full semiconductor product lifecycle - from characterization, modeling, reliability, and design de-bug, to qualification and production test.. The company operates in two reportable segments namely Probe Cards Segment and the Systems Segment. Sales of probe cards and analytical probes are included in the Probe Cards Segment, while sales of probe stations and thermal sub-systems are included in the Systems Segment. Probe cards generate the maximum revenue from its operations. It offers multiple product lines which include analytical probes, probe stations, thermal sub-systems, and related services.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.